BRAF

Serine/threonine-protein kinase B-raf

263,882 patent compounds predicted against BRAF, 160,358 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL84259	0.69	20/20
SCHEMBL69214	0.67	20/20
SCHEMBL69215	0.67	20/20
SCHEMBL84262	0.66	20/20
SCHEMBL69547	0.64	20/20
SCHEMBL69548	0.64	20/20
SCHEMBL68328	0.64	20/20
SCHEMBL68091	0.64	20/20
SCHEMBL68092	0.64	20/20
SCHEMBL68835	0.64	20/20
SCHEMBL68836	0.64	20/20
SCHEMBL67330	0.63	20/20
SCHEMBL67331	0.63	20/20
SCHEMBL91501	0.63	20/20
SCHEMBL91575	0.63	20/20
SCHEMBL68275	0.63	20/20
SCHEMBL68276	0.63	20/20
SCHEMBL67068	0.63	20/20
SCHEMBL67069	0.63	20/20
SCHEMBL68428	0.63	20/20

Germline variants in BRAF on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full BRAF gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to BRAF by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	PHASE2/PHASE3	NOT_YET_RECRUITING
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer	PHASE2	COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer	PHASE2	UNKNOWN
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations	PHASE1/PHASE2	COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	PHASE1/PHASE2	COMPLETED
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma	PHASE1/PHASE2	COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations	PHASE2	ACTIVE_NOT_RECRUITING
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma	PHASE2	COMPLETED
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma	PHASE2	COMPLETED
Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma	PHASE2	ACTIVE_NOT_RECRUITING
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations	PHASE2	ACTIVE_NOT_RECRUITING
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma	PHASE2	ACTIVE_NOT_RECRUITING
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma	PHASE2	COMPLETED
LUT017 Gel for Venous Leg Ulcers and Chronic Non-Healing Skin Wounds in Adults	PHASE1	NOT_YET_RECRUITING
A Study of ASN007 in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Study of LUT017 Gel to Improve Healing of Skin Wounds After Removal of Benign Lesions in Healthy Adults	PHASE1	NOT_YET_RECRUITING
Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors	PHASE1	COMPLETED
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma	PHASE1	ACTIVE_NOT_RECRUITING
HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors	PHASE1	UNKNOWN
Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma	PHASE1	WITHDRAWN
Molecular Phenotype Changes and Personalized Treatment for CRPC	nan	UNKNOWN
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation	nan	COMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment	nan	ACTIVE_NOT_RECRUITING
Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma	nan	NO_LONGER_AVAILABLE
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Immune Monitoring in Metastatic Melanoma	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a BRAF binder may also engage these)

Protein	Name	Similarity
Q04982	—	1.000	Q04982 →
P34908	—	1.000	P34908 →
P28028	—	1.000	P28028 →
P04627	—	0.991	P04627 →
ARAF	Serine/threonine-protein kinase A-Raf	0.991	landscape →
RAF1	RAF proto-oncogene serine/threonine-protein kinase	0.989	landscape →
Q99N57	—	0.989	Q99N57 →
A7E3S4	—	0.989	A7E3S4 →
Q9ESL4	—	0.989	Q9ESL4 →
P09560	—	0.988	P09560 →
P05625	—	0.987	P05625 →
O19004	—	0.987	O19004 →
P14056	—	0.986	P14056 →
Q62136	—	0.986	Q62136 →
Q5R5M7	—	0.985	Q5R5M7 →
P27966	—	0.984	P27966 →
MAP3K20	Mitogen-activated protein kinase kinase kinase 20	0.984	landscape →
P11345	—	0.984	P11345 →
A7MBL8	—	0.983	A7MBL8 →
Q99JP0	—	0.983	Q99JP0 →
MAP4K3	Mitogen-activated protein kinase kinase kinase kinase 3	0.983	landscape →
Q8N556	—	0.982	Q8N556 →
MAP3K7	Mitogen-activated protein kinase kinase kinase 7	0.981	landscape →
Q62925	—	0.981	Q62925 →
A0JNJ1	—	0.981	A0JNJ1 →
Q6F6B3	—	0.980	Q6F6B3 →
Q96NE9	—	0.980	Q96NE9 →
P53666	—	0.980	P53666 →
BCR	Breakpoint cluster region protein	0.980	landscape →
Q92625	—	0.980	Q92625 →